Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
Xanthopurpurin (CAS No.: 518-83-2) is a natural anthraquinone compound with significant oral biological activity. As an important natural product, isorubifurin is mainly isolated from the rhizome of the Rubiaceae plant Rubia akane. In recent years, with the rapid development of natural product pharmacology, isodiperinin has become a research hotspot due to its diverse biological activities, especially its potential in antiviral, antitumor, and immunomodulatory properties. This paper aims to systematically review the chemical structure and physicochemical properties of isoperiprino, plant origin and extraction process, pharmacological activity and mechanism of action, druggability evaluation, and pharmacokinetic characteristics, and finally discuss its clinical application prospects and future development directions, providing theoretical basis and reference for related research.
Isabolithiol belongs to the anthraquinone class of compounds, with a molecular formula of C14H8O4 and a molecular weight of 240.2140. Its chemical core is the anthraquinone framework, specifically 1,3,8-trihydroxyanthraquinone, which has three hydroxyl substituents that impart specific chemical and biological activities. The LogP value of isocabrolin was 2.7555, indicating moderate lipid solubility, which facilitates cell membrane penetration and oral absorption. Its topological pole surface area (TPSA) is 74.6 Ų, indicating moderate polarity that facilitates binding to biological targets. Low water solubility (0.0911 mg/mL), which may limit its solubility and bioavailability in the aqueous phase. The low penetration rate of the blood-brain barrier suggests its limited distribution in the central nervous system. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. The Ames-induced mutagenic test value was 1.2, indicating a low genotoxicity risk and good safety.
Isovabisin mainly comes from the rhizome of the Rubiaceae plant Rubia akane. Plants of the Rubia genus are widely distributed across Asia and have traditionally been used as dyes and medicinal herbs. As one of its main active ingredients, isoprebisin has significant medicinal value.
The process for extracting isoovabisin typically includes the following steps: First, the dried Rubia akane rhizome is crushed and extracted by reflux using polar solvents such as ethanol or methanol. After concentration, the extract is extracted by liquid-liquid extraction to remove impurities. It is then separated and purified by silica gel column chromatography or high-performance liquid chromatography (HPLC), ultimately obtaining high-purity isoperiferin. In recent years, the application of ultrasound-assisted extraction and microwave-assisted extraction technologies has improved extraction efficiency and purity, reduced solvent usage, and aligned with green chemistry principles.
Isovabisin exhibits broad-spectrum antiviral activity, especially showing significant inhibitory effects against rotavirus and HIV viruses. In vitro experiments have shown that isabolitin can inhibit viral replication and infection processes, reducing viral load. Its anti-rotavirus effect may be achieved by interfering with the assembly of viral capsid proteins or blocking the binding of the virus to host cells; HIV suppression may involve suppression of reverse transcriptase activity and interference with viral integration processes.
Isabelian has a strong inhibitory effect on collagen-induced platelet aggregation. Platelet aggregation is a key step in thrombosis formation, and its abnormal activation is closely related to cardiovascular and cerebrovascular diseases. Isovasin may reduce thrombosis risk by inhibiting collagen-mediated platelet activation and has potential antithrombotic therapeutic value.
Isabazin can prevent peanut allergic reactions, demonstrating its potential in regulating the immune system. Related studies suggest that isodiperithin may alleviate allergic symptoms by inhibiting mast cell degranulation and regulating Th1/Th2 immune balance, showing potential as an adjunctive treatment for allergic diseases.
Isovaru shows significant anti-proliferative and pro-apoptotic effects in various tumor cell lines. Its antitumor activity involves multiple signaling pathways and molecular targets, including MCL1, BCL2, STAT3, MMP2, TOP1, HIF1A, TOP2A, MAPK1, ESR1, and CYP19A1. By regulating these key targets, isovarutin can inhibit tumor cell proliferation, migration, and invasion, induce cell cycle arrest and apoptosis, and demonstrate strong anti-cancer potential.
The multi-target mechanism of isovalin is the foundation of its broad pharmacological activity. The specific mechanism is as follows:
MCL1 and BCL2: These two anti-apoptotic proteins are important regulators of cell survival. Isabazin promotes tumor cell apoptosis and enhances chemotherapy sensitivity by downregulating the expression of MCL1 and BCL2.
STAT3 signaling pathway: STAT3 is abnormally activated in various tumors, promoting cell proliferation and immune evasion. Isovabisin inhibits STAT3 phosphorylation, blocks its transcriptional activity, and suppresses tumor growth.
MMP2: Matrix metalloproteinase 2 is involved in stromal degradation and metastasis in tumor cells. Isaboxyl inhibits MMP2 expression, preventing tumor cell invasion and metastasis.
TOP1 and TOP2A :D NA topoisomerases are key enzymes for DNA replication and transcription in cells. Isabazin inhibits the activities of TOP1 and TOP2A, interferes with normal DNA metabolism in tumor cells, and induces cell death.
HIF1A: Hypoxia-inducing factor 1α regulates the tumor's adaptive response. Isovabisin inhibits HIF1A expression, blocks tumor hypoxia adaptation, and inhibits angiogenesis.
MAPK1: A signaling pathway involved in cell proliferation and differentiation. Isovarifurin regulates MAPK1 activity and influences tumor cell fate.
ESR1 and CYP19A1: Estrogen receptors and aromatase, respectively, involved in the development of hormone-dependent tumors. Isolitriol may exert anti-breast cancer effects by regulating these two targets.
Additionally, the inhibitory effect of isosperithonin on platelet aggregation may involve its intervention in collagen receptors and downstream signaling pathways, weakening platelet activation. Its antiviral mechanism may be achieved by interfering with viral replication and interaction with host cells.
The druggability parameters of isorobin indicate its promising potential for drug development. The molecular weight of 240.2140 complies with the requirements for oral medications under the Lipinski rules. A LogP value of 2.7555 indicates moderate lipid solubility, which is beneficial for cell membrane permeability. The TPSA was 74.6, indicating moderate polarity, which helps with target binding and bioavailability.
Low water solubility (0.0911 mg/mL) may limit oral absorption and bioavailability, requiring formulation optimization techniques such as nanocarriers and solid dispersions to improve solubility. The blood-brain barrier has low permeability, reducing the risk of central nervous system side effects. hERG channel inhibition is negative, indicating better cardiac safety. The Ames test has low mutagenicity and relatively high safety.
Currently, pharmacokinetic data on isoacetifurin are relatively limited. Preliminary in vivo studies show it is well absorbed orally, but its metabolic pathways and clearance mechanisms still require further study. In the future, systematic pharmacokinetics and toxicological evaluations should be conducted to clarify its in vivo behavioral characteristics, providing a foundation for clinical development.
As a versatile natural product, isoubilin demonstrates broad pharmacological activity and good safety, showing significant potential for clinical development. Its antiviral effects provide a new candidate drug direction for treating rotavirus infection and HIV. Antitumor activity covers a variety of tumor-related targets, with particularly outstanding performance in hormone-dependent tumors and invasive metastasis. In the future, it may be used as an adjunct to monotherapy or combination chemotherapy.
Additionally, Isabriolin's role in anti-platelet aggregation and allergic reactions offers new ideas for the treatment of cardiovascular and cerebrovascular diseases and allergic conditions. By leveraging its druggability advantages and improving drug design and dosage forms, it is expected to overcome the limitations of insufficient water solubility and enhance clinical application value.
Future research should focus on the following directions:
In-depth mechanism research: Combining multi-omics techniques, systematically analyzing the action network and signaling pathways of isabilian to clarify its multi-target synergistic mechanism.
Pharmacokinetics and toxicology: Improving metabolism, distribution, excretion, and long-term safety evaluation in vivo to lay the foundation for clinical trials.
Dosage Form Development: Utilizing nanotechnology, solid dispersions, and other novel formulations to enhance bioavailability and targetability.
Preclinical and clinical research: Conduct systematic animal models and clinical trials to verify efficacy and safety, and promote translational applications.
Structural optimization and derivative development: Enhancing activity and pharmacokinetic properties through chemical modification, expanding its range of applications.
Isovabisin, a natural anthraquinone compound derived from Rubia akane, shows broad application prospects in antiviral, anti-tumor, antiplatelet aggregation, and anti-allergic fields due to its unique chemical structure and multi-target pharmacological activity. Its excellent druggability parameters and safety provide favorable conditions for drug development. In the future, through in-depth mechanistic research, pharmacokinetic evaluation, and formulation optimization, isodifurazin is expected to become an important candidate molecule in the development of natural product drugs, providing new strategies and options for the treatment of related diseases. Ongoing basic and clinical research will drive isoalin from the laboratory to clinical practice, benefiting patients.
